ETR:EVT Evotec (EVT) Stock Price, News & Analysis → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free EVT Stock Alerts €9.64 -4.54 (-32.02%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range€8.52▼€13.2050-Day Range€9.64▼€14.4752-Week Range€12.61▼€24.44Volume21.19 million shsAverage Volume1.36 million shsMarket Capitalization$1.71 billionP/E RatioN/ADividend Yield2.63%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Evotec alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Evotec Stock (ETR:EVT)Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Read More EVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVT Stock News HeadlinesApril 22, 2024 | finance.yahoo.comSernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of DirectorsApril 20, 2024 | finanznachrichten.deEvotec SE: Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis TreatmentsApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 18, 2024 | markets.businessinsider.comEQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatmentsApril 17, 2024 | finanznachrichten.deEvotec beruft Aurélie Dalbiez in den VorstandApril 17, 2024 | finanznachrichten.deEvotec SE: Evotec welcomes Aurélie Dalbiez as Chief People OfficerApril 17, 2024 | markets.businessinsider.comEQS-News: Evotec welcomes Aurélie Dalbiez as Chief People OfficerApril 17, 2024 | finance.yahoo.comEvotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024April 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 13, 2024 | finanznachrichten.deANALYSE: Deutsche Bank hebt Evotec auf 'Buy' - Frust nach Chef-Abgang überwundenMarch 29, 2024 | finanznachrichten.deBiotech Report: Evotec klettern, Qiagen festMarch 15, 2024 | finanznachrichten.deEvotec-Aktie: Das wird spannendMarch 6, 2024 | markets.businessinsider.comEQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinicFebruary 22, 2024 | finanznachrichten.deEvotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?Evotec Aktie sucht Boden: Kommt jetzt die große Wende nach oben?February 6, 2024 | finanznachrichten.deEvotec: Aktie fällt und fällt - das ist jetzt wichtigFebruary 3, 2024 | finanznachrichten.deEvotec-Aktie fällt unter wichtige Marke. Wie sollen Anleger jetzt reagieren?January 22, 2024 | finance.yahoo.comEvotec SE: Invitation to Conference CallJanuary 8, 2024 | markets.businessinsider.comEQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers SquibbJanuary 8, 2024 | finance.yahoo.comEvotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers SquibbJanuary 3, 2024 | markets.businessinsider.comEQS-Adhoc: Evotec announces CEO transitionJanuary 3, 2024 | finanznachrichten.deEvotec SE: Evotec Announces CEO TransitionJanuary 3, 2024 | markets.businessinsider.comEQS-News: Evotec announces CEO transitionJanuary 3, 2024 | finance.yahoo.comEvotec Announces CEO TransitionDecember 14, 2023 | finance.yahoo.comEvotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune DiseasesDecember 6, 2023 | msn.comEvotec partner Jingxin receives approval for EVT201 in ChinaDecember 6, 2023 | markets.businessinsider.comEQS-News: Evotec-partner Jingxin receives approval for EVT201 in ChinaNovember 8, 2023 | markets.businessinsider.comEvotec 9-month Adj. EBITDA, Revenues Rise; Confirms FY23, Mid-term OutlookSee More Headlines Receive EVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolETR:EVT CUSIPN/A CIKN/A Webwww.evotec.com Phone+49-40-560810FaxN/AEmployees5,086Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.53) Trailing P/E RatioN/A Forward P/E Ratio45.76 P/E Growth0.98Net Income$-94,980,000.00 Net Margins-11.57% Pretax MarginN/A Return on Equity-8.02% Return on Assets0.17% Debt Debt-to-Equity Ratio51.61 Current Ratio2.16 Quick Ratio2.97 Sales & Book Value Annual Sales$820.80 million Price / Sales2.08 Cash Flow€2.79 per share Price / Cash Flow3.45 Book Value€6.45 per share Price / Book1.49Miscellaneous Outstanding Shares177,190,000Free FloatN/AMarket Cap$1.71 billion OptionableNot Optionable Beta1.11 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Mario Polywka DPHIL (Age 61)Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board Dr. Werner Lanthaler M.B.A. (Age 56)MPA, Ph.D., Member of Management Board Comp: $1.32MDr. Cord Dohrmann Ph.D. (Age 60)Chief Scientific Officer & Member of Management Board Comp: $804kDr. Craig Johnstone Ph.D. (Age 54)COO & Member of Management Board Comp: $712kDr. Matthias Evers Ph.D. (Age 51)Chief Business Officer & Member of Management Board Comp: $636kMs. Laetitia Rouxel (Age 50)CFO & Member of Management Board Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingMr. Volker BraunSenior VP and Global Head of Investor Relations & ESGDr. Christian DargelEVP Global Head of Legal & ComplianceGabriele HansenSenior VP & Head of Global Corporate Communications & MarketingMore ExecutivesKey CompetitorsMorphoSysETR:MORShop Apotheke EuropeETR:SAECompuGroup Medical SE & Co. KGaAETR:COPGerresheimerETR:GXIRHÖN-KLINIKUM AktiengesellschaftETR:RHKView All Competitors EVT Stock Analysis - Frequently Asked Questions How have EVT shares performed in 2024? Evotec's stock was trading at €21.28 on January 1st, 2024. Since then, EVT shares have decreased by 54.7% and is now trading at €9.64. View the best growth stocks for 2024 here. What other stocks do shareholders of Evotec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC). This page (ETR:EVT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.